Metformin NDMA Contamination Class Action Settlement
Metformin NDMA Contamination Class Action Settlement
Teva Pharmaceuticals, Granules, and Heritage Pharmaceuticals agreed to pay a combined $5.55 million to resolve claims that their generic metformin-containing drugs were contaminated with NDMA and did not meet FDA quality standards. Anyone in the United States who paid for a metformin-containing drug from any of those companies between July 20, 2015 and June 2, 2020 can file a claim for a pro-rata share of the fund, with no documentation required for individual consumers.
Settlement fund
$5.55M
Common fund
Top payout
Pro-rata share
No proof needed for consumers
Claim deadline
Jul 10, 2026
45 days remaining
You may be owed money
Filing is free and takes a few minutes. Deadline: Jul 10, 2026.
Do you qualify?
You are a Class Member if ALL of the following apply:
- You are a person or entity in the United States (including its territories and possessions).
- You paid any amount of money for a metformin-containing drug intended for personal or household use that was manufactured, distributed, or sold by Teva, Granules, or Heritage Pharmaceuticals between July 20, 2015 and June 2, 2020.
- No receipts or proof of purchase are required for individual consumers to submit a claim.
- Excluded: Teva, Granules, and Heritage and their subsidiaries and affiliates; anyone who purchased metformin for resale; anyone who purchased directly from the settling defendants; fully insured health plans; pharmaceutical benefit managers; federal, state, and local governmental entities prohibited from bringing these claims through private counsel; and the presiding judge and their immediate family.
Not sure if you qualify? Call the Settlement Administrator at 1-866-302-6835, or visit InReMetforminSettlement.com.
What happened
This class action lawsuit alleges that Teva Pharmaceuticals, Granules, and Heritage Pharmaceuticals (doing business as Avet Pharmaceuticals) falsely advertised their generic metformin-containing drugs as equivalent to the brand-name products Glucophage and Glucophage XR. The plaintiffs claim those generic drugs were contaminated with N-nitrosodimethylamine (NDMA), a probable human carcinogen, and did not meet FDA quality standards for metformin. As a result, consumers and third-party payors paid for a drug they allege they would not have purchased had they known the full picture. This case does not include personal injury or wrongful death claims.
Teva, Granules, and Heritage deny the allegations and deny any wrongdoing or liability, and the Court has not made any determination that the settling defendants violated any law. The parties agreed to settle to avoid the cost, risk, and time of continued litigation. The lawsuit is continuing against the remaining defendants, Amneal Pharmaceuticals and Walmart, who are not part of this settlement.
How to file a claim
-
1. Confirm you are eligible
You must have paid for a metformin-containing drug intended for personal or household use that was manufactured, distributed, or sold by Teva, Granules, or Heritage Pharmaceuticals between July 20, 2015 and June 2, 2020. Third-party payors who reimbursed those purchases also qualify.
-
2. Gather your information
Individual consumers do not need receipts or documentation to file. Third-party payors with claims of $100,000 or more must include transaction data. For smaller TPP claims, data may still be requested by the administrator, so keep records available. A TPP filing template and applicable NDC list can be downloaded at InReMetforminSettlement.com/file-a-claim. Your payment will be calculated pro rata based on the amount and price of metformin purchased and the total number of valid claims.
-
3. File online or by mail
Submit the Claim Form online at claimform.inremetforminsettlement.com so it is received by July 10, 2026, or mail a paper Claim Form so it is received by July 10, 2026 at: In re Metformin Marketing and Sales Practices Litigation, c/o A.B. Data, Ltd., P.O. Box 173012, Milwaukee, WI 53217. Consumer identities are kept confidential unless you consent to disclosure. The Settlement Agreement and additional documents are available at InReMetforminSettlement.com.
-
4. Receive your payment
Payments are issued after the Court grants final approval at the August 12, 2026 Fairness Hearing and any appeals are resolved. The appeal process can take a year or more. No follow-up is required once your claim is submitted.
Key dates
- Jul 10, 2026 Opt-out & objection deadline Upcoming
- Jul 10, 2026 Claim filing deadline Upcoming
- Aug 12, 2026 Final Fairness Hearing (10:00 a.m. ET, virtual via Microsoft Teams) Upcoming
- TBD after final approval Payments issued to claimants Pending
The Fairness Hearing is scheduled for August 12, 2026 at 10:00 a.m. ET, held virtually via Microsoft Teams at a link to be circulated by the Court. The Court may move the hearing, so check InReMetforminSettlement.com for updates.
Where the money is going
This is a non-reversionary common fund split between two settlements: $3 million from Teva and $2.55 million from Granules and Heritage. Attorneys' fees, service awards, and notice and administration costs come out of the $5.55 million before payments are calculated for class members.
All amounts listed above are pending and subject to final court approval at the Fairness Hearing. The Court may award less than the amounts requested. If valid claims exceed what remains of the fund, payments will be reduced on a pro rata basis.
Common questions
How much money will I receive?
The exact per-person payment is not yet known. After attorneys' fees, service awards, and administration costs are paid from the $5.55 million fund, the remainder is distributed pro rata to eligible class members who filed valid claims. Your share depends on the quantity and price of metformin you purchased during the class period and the total number of valid claims submitted. Payments may be modest depending on claim volume.
Do I need to submit proof of purchase?
No receipts or documentation are required for individual consumers. You submit on your own attestation. Third-party payors with claims of $100,000 or more must provide transaction data. For smaller TPP claims the administrator may still request data, so keep records available. Consumer submissions are kept confidential unless you consent to disclosure.
What if I didn’t receive a notice?
You can still file a claim even if you did not receive a notice. Notice was sent based on available purchase records, but many people who qualify did not receive a direct mailing. If you paid for a metformin-containing drug from Teva, Granules, or Heritage for personal or household use between July 20, 2015 and June 2, 2020, you are likely a Class Member and can submit a Claim Form. For help, visit InReMetforminSettlement.com or call 1-866-302-6835.
Does staying in the class affect my right to sue later?
Yes. Unless you opt out by submitting a written exclusion request received by July 10, 2026, you will be bound by the Court's decisions and you will release the legal claims covered by this settlement against Teva, Granules, and Heritage. That means you cannot separately sue those defendants for the same claims. The full release language is in the Settlement Agreement, available at InReMetforminSettlement.com. Opting out means you receive no payment from this settlement.
When will payments be sent out?
The Court will hold the Fairness Hearing on August 12, 2026 at 10:00 a.m. ET via Microsoft Teams. Payments will only be issued after final approval is granted and any appeals are resolved. The appeal process can take a year or more. No action is required after a valid Claim Form is submitted.
Dapeer Law, P.A.
Consumer class action attorneys based in South Florida. We track settlements so you don’t have to.
Similar open settlements
This page is for informational purposes only and does not constitute legal advice. Dapeer Law, P.A. is not the administrator of this settlement and is not affiliated with Teva Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries Ltd.; Actavis Pharma, Inc.; Actavis LLC; Granules USA, Inc.; Granules Pharmaceuticals, Inc.; and Heritage Pharmaceuticals, Inc. (d/b/a Avet Pharmaceuticals Inc.), A.B. Data, Ltd. (the Settlement Administrator), or Class Counsel James E. Cecchi and Donald Ecklund of Carella, Byrne, Cecchi, Brody & Agnello, P.C. The case is In re Metformin Marketing and Sales Practices Litigation, Civil Action No. 2:20-cv-02334-MCA-MAH, pending in the U.S. District Court for the District of New Jersey before the Honorable Madeline C. Arleo. Class representatives are Joseph Brzozowski, Jacqueline Harris, Kristen Weineinger, Michael Hann, Masao Hendrix, MSP Recovery Claims Series LLC, County of Monmouth, and Ohio Carpenters' Health Fund. Teva, Granules, and Heritage denies wrongdoing. This website is attorney advertising. Past results do not guarantee future outcomes.
